GlassScriptPhysician profile
Mayda Arias
NPI 1205851797
$3,507.48
in general payments reported to CMS, 2019-2025
39 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $55.05 · 2022: $34.80 · 2023: $453 · 2024: $1,326 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,200 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,200.40 |
| Education | $103.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $493.98 | 2019-2025 | Enhertu, Tagrisso |
| Pfizer INC. | $427.12 | 2019-2025 | |
| Janssen Biotech, INC. | $409.86 | 2022-2025 | Talvey, Darzalex, Imbruvica |
| Novartis Pharmaceuticals Corporation | $286.12 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $199.26 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Tersera Therapeutics LLC | $156.13 | 2024-2025 | Zoladex |
| Daiichi Sankyo INC. | $137.26 | 2024-2025 | Enhertu, Datroway |
| Alnylam Pharmaceuticals INC. | $125.00 | 2023 | Amvuttra |
| Genzyme Corporation | $120.34 | 2024-2025 | |
| Seagen INC. | $118.74 | 2023 | Tukysa |
| Genentech USA, INC. | $109.28 | 2024-2025 | Tecentriq, Phesgo, Kadcyla |
| Celgene Corporation | $108.55 | 2024-2025 | Reblozyl, Pomalyst |
| Tactile Systems Technology INC | $59.62 | 2024 | Flexitouch Plus, Entre Plus |
| Sobi, INC | $57.78 | 2025 | |
| Aveo Pharmaceuticals, INC. | $56.09 | 2024-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayda Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.